杜普伊特倫攣縮症市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、疾病類型、最終用途、地區和競爭格局分類，2021-2031年）

全球杜普伊特倫氏攣縮症市場預計將從 2025 年的 46.8 億美元成長到 2031 年的 61.5 億美元，複合年成長率為 4.66%。

杜普伊特倫攣縮症是一種進行性結締組織疾病，其特徵是掌筋膜增厚，導致膠原蛋白結節和索狀物的形成，最終造成手指永久性攣縮。市場成長的主要促進因素是全球人口老化和糖尿病等風險因素的增加，這些因素導致患者群體不斷擴大。此外，患者對微創治療的偏好日益成長，以及治療方法的日益普及，也擴大了可治療的病例範圍。根據美國整形外科醫師協會的數據，預計到2024年，其會員外科醫師將進行208,480例手部重組手術，顯示包括Dupuytren氏攣縮在內的功能性手術需求持續且顯著。

阻礙市場擴張的主要障礙之一是現有治療方案的高疾病復發率。無論患者選擇手術切除術或微創酶注射，由於缺乏永久治療方法，往往需要反覆干預，從而加重患者和支付方的經濟負擔。長期療效問題，加上通常適用於高成本生物療法的嚴格報銷政策，可能會限制在注重成本的醫療保健市場中採用高階治療方案。

市場促進因素

全球杜普伊特倫攣縮症市場的主要成長動力是研發投入的激增，這些投入主要集中在新型治療方法上，而這又源於對安全性更高的非手術治療方法的迫切需求。生技公司正積極推進其臨床研發管線，以期推出現有膠原蛋白酶療法的重組替代方案，從而減少對侵入性手術的依賴。例如，Connext公司於2024年7月宣布，其在澳洲進行的I/II期臨床試驗中已完成CNT201的首劑生物製藥，這標誌著檢驗新型重組膠原蛋白酶治療方法療效的重要一步。預計這種研發活動的活性化將催生出療效更佳、成本更低的治療方法，從而豐富市場競爭格局並擴大市場進入。

同時，全球發病率的上升，尤其是在老年人族群中，導致需要長期醫療管理的患者數量不斷增加。隨著預期壽命的延長，遺傳易感性和生活方式相關風​​險的累積，使得基層醫療機構的診斷病例顯著增加，直接擴大了目標患者群體。 2024年7月發表在medRxiv上的一項研究分析了全科診所的註冊數據，發現研究人群中杜普伊特倫攣縮症的總體患病率為1.99%，其中老年人群的患病率顯著高於其他人群。患者數量的增加導致對現有藥物治療的巨大商業性需求。例如，Endo公司在2024年11月公佈的第三季XIAFLEX系列產品總營收為1.28億美元，證實了這項臨床需求所蘊含的顯著規模經濟效益。

市場挑戰

高復發率仍是全球杜普伊特倫攣縮症市場持續成長的一大障礙。這種臨床現實導致患者需要反覆治療，使人們對昂貴治療方案的長期經濟價值產生質疑。在症狀頻繁復發、導致醫療成本增加的情況下，保險公司和支付方越來越不願意核准高成本的生物製藥療法和微創手術。因此，這種質疑導致了嚴格的報銷標準，優先考慮傳統的、成本較低的手術方法，而非創新但更昂貴的藥物治療方案，從而限制了新型治療藥物生產商的收入潛力。

2024年，英國手外科協會透過對比臨床數據強調了這個問題：接受微創膠原蛋白酶注射治療的患者一年內再次手術率為14.6%，而接受外科切除術的患者再次手術率則顯著降低至3.4%。這種初始療效的差異加劇了注重成本的醫療系統不願廣泛資助先進的非手術治療，直接阻礙了高階生物製藥市場佔有率的成長。

市場趨勢

經皮筋膜切開術 (PNA) 的日益普及標誌著治療理念正發生重大轉變，即從激進的手術切除轉向微創、經濟高效的治療方法，優先考慮快速恢復功能。隨著越來越多的臨床醫生尋求可高度重複的門診手術，以最大限度地減少患者的恢復時間和醫療成本，尤其是在傳統手術風險過高的情況下，這一趨勢正在加速發展。近期臨床數據支持了先進的針刺技術在恢復手指功能方面的有效性，且無需切除術相關的大規模復健過程。根據 2025 年 1 月《肌肉骨骼外科》雜誌的一項研究，一項評估改良 PNA 技術的研究報告顯示，受累手指的攣縮平均改善率達 83%，短期復發率顯著降低至 14.2%。這使得該手術成為保留手指功能的有效一線治療方案。

同時，市場正著力將輔助放射線治療作為一種策略性治療手段，以延緩疾病進展並解決原發治療後高復發率的問題。這種方法代表著治療模式向混合治療方法模式的轉變，即在淋巴結清掃或有限釋放後立即進行放射線治療，惰性纖維母細胞並阻止膠原蛋白索的再形成。目前，重點在於確定這種聯合治療的安全性、擴大保險覆蓋範圍並提高臨床接受度。正如2025年2月《手外科雜誌》（歐洲版）報道，一項評估輔助放射線治療安全性的隨機對照試驗證實了其良好的耐受性。記錄的不利事件中有89%為輕度且可自癒，這支持了其作為一種低風險輔助性治療在長期疾病控制中的作用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球杜普伊特倫攣縮症市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 類型（診斷（身體檢查、X光檢查）、治療（手術、放射線治療、針刺筋膜切開術、類固醇注射、酵素注射、職能治療、其他））
  • 依疾病類型（I型、II型、III型）
  • 依最終使用者（醫院、診所、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美杜普伊特倫攣縮症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲杜普伊特倫攣縮症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區杜普伊特倫攣縮症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲杜普伊特倫攣縮症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲杜普伊特倫攣縮症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球杜普伊特倫攣縮症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Dupuytren's Disease Market is projected to expand from a valuation of USD 4.68 Billion in 2025 to USD 6.15 Billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 4.66%. Dupuytren's disease is defined as a progressive connective tissue disorder involving the thickening of the palmar fascia, which results in the development of collagen nodules and cords that force fingers into permanent contracture. Market growth is primarily supported by an aging global population and the increasing prevalence of risk factors such as diabetes, both of which widen the target patient demographic. Additionally, a growing patient preference and availability of minimally invasive treatments have expanded the range of manageable cases. Data from the American Society of Plastic Surgeons indicates that 208,480 reconstructive hand surgeries were performed by member surgeons in 2024, highlighting the consistent and substantial demand for functional interventions, including those required for Dupuytren's contracture.

One significant obstacle potentially hindering market expansion is the high rate of disease recurrence linked to current treatment options. Whether patients choose surgical fasciectomy or minimally invasive enzymatic injections, the absence of a permanent cure frequently leads to the need for repeat interventions, compounding the economic burden on both patients and payers. This issue regarding long-term efficacy, coupled with strict reimbursement policies often applied to high-cost biologic therapies, threatens to restrict the adoption of premium treatment solutions in cost-conscious healthcare markets.

Market Driver

A primary engine for growth in the Global Dupuytren's Disease Market is the surge in research and development dedicated to novel therapeutics, driven by an urgent demand for non-surgical interventions with enhanced safety profiles. Biotechnology companies are actively progressing their clinical pipelines to introduce recombinant alternatives to existing collagenase therapies, with the goal of reducing reliance on invasive surgical procedures. For example, Connext announced in July 2024 that it had administered the first dose of CNT201 to patients in a Phase 1/2 clinical trial in Australia, representing a pivotal step toward validating a new genetically recombinant collagenase treatment. This intensification of R&D activity is expected to diversify the competitive landscape and broaden market access by developing treatments that offer superior efficacy or cost benefits compared to current biologics.

Simultaneously, the increasing global prevalence of the condition, particularly within aging demographics, is expanding the volume of patients necessitating long-term medical management. As life expectancy increases, the accumulation of genetic predispositions and lifestyle-related risks has led to a measurable rise in diagnosed cases in primary care settings, directly enlarging the addressable patient pool. A study published via medRxiv in July 2024 analyzed general practice registration data and identified an overall Dupuytren's disease prevalence of 1.99% in the population studied, with rates peaking significantly in older age groups. This growing patient base translates into substantial commercial demand for established pharmaceutical interventions, as evidenced by Endo, Inc., which reported total third-quarter revenues of $128 million for its XIAFLEX franchise in November 2024, underscoring the significant economic scale fueled by this clinical need.

Market Challenge

The high rate of disease recurrence remains a critical barrier impeding the sustainable growth of the Global Dupuytren's Disease Market. This clinical reality generates a cycle of repeat interventions that calls into question the long-term economic value of premium treatment options. Insurance providers and payers are increasingly reluctant to authorize high-cost biologic therapies or minimally invasive procedures when the condition frequently returns, necessitating additional medical expenditures. Consequently, this skepticism results in stringent reimbursement criteria that favor traditional, lower-cost surgical methods over innovative but expensive pharmaceutical solutions, thereby limiting the revenue potential for manufacturers of novel therapeutics.

In 2024, the British Society for Surgery of the Hand highlighted this issue with comparative clinical data showing that patients treated with minimally invasive collagenase injections experienced a re-intervention rate of 14.6 percent within one year, whereas those undergoing surgical fasciectomy saw a significantly lower rate of 3.4 percent. This disparity in early efficacy reinforces the hesitation of cost-sensitive healthcare systems to broadly fund advanced non-surgical treatments, directly hampering the market share expansion of premium biological products.

Market Trends

The increasing adoption of Percutaneous Needle Aponeurotomy (PNA) signifies a major shift toward minimally invasive, cost-effective interventions that prioritize rapid functional recovery over aggressive surgical excision. This trend is accelerating as clinicians seek repeatable outpatient procedures that minimize patient downtime and healthcare costs, especially for cases where traditional open surgery presents disproportionate risks. Recent clinical data supports the efficacy of refined needle techniques in restoring hand function without the extensive rehabilitation associated with fasciectomy. According to Musculoskeletal Surgery in January 2025, a study evaluating a modified PNA technique reported a mean contracture correction of 83 percent across affected digits, with a notably low short-term recurrence rate of 14.2 percent, positioning the procedure as a viable first-line treatment for preserving hand mechanics.

Concurrently, the market is observing the integration of adjuvant radiotherapy as a strategic modality to inhibit disease progression and address the challenge of high recurrence rates following primary interventions. This approach represents a move toward hybrid treatment models where radiotherapy is applied immediately after nodule disruption or limited release to deactivate fibroblasts and prevent the reforming of collagen cords. The focus is currently on establishing the safety profile of this combination to encourage broader payer coverage and clinical acceptance. As reported in the Journal of Hand Surgery (European Volume) in February 2025, a randomized controlled trial assessing the safety of adjuvant radiotherapy confirmed its tolerability, revealing that 89 percent of recorded adverse events were mild and self-limiting, thereby supporting its role as a low-risk adjunct for long-term disease control.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC

Report Scope

In this report, the Global Dupuytren's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dupuytren's Disease Market, By Type

• Diagnosis (Physical Examination, X-ray)
• Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others)

Dupuytren's Disease Market, By Disease Type

• Type I
• Type II
• Type III

Dupuytren's Disease Market, By End-use

• Hospitals
• Clinics
• Academic & Research Institute
• Others

Dupuytren's Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dupuytren's Disease Market.

Available Customizations:

Global Dupuytren's Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dupuytren's Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others))
  • 5.2.2. By Disease Type (Type I, Type II, Type III)
  • 5.2.3. By End-use (Hospitals, Clinics, Academic & Research Institute, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Dupuytren's Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Type
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dupuytren's Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Dupuytren's Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Dupuytren's Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By End-use

7. Europe Dupuytren's Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Type
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dupuytren's Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Dupuytren's Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Dupuytren's Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Dupuytren's Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Dupuytren's Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By End-use

8. Asia Pacific Dupuytren's Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Type
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dupuytren's Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Dupuytren's Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Dupuytren's Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Dupuytren's Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Dupuytren's Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Dupuytren's Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Type
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dupuytren's Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Dupuytren's Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Dupuytren's Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By End-use

10. South America Dupuytren's Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Type
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dupuytren's Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Dupuytren's Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Dupuytren's Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dupuytren's Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Nantong Jinghua Pharmaceutical Co., Ltd
• 15.5. Actiza Pharmaceutical Private Limited
• 15.6. Endo International plc
• 15.7. Spear Pharmaceuticals
• 15.8. Hikma Pharmaceuticals PLC
• 15.9. Bristol-Myers Squibb
• 15.10. Glaxosmithkline PLC

16. Strategic Recommendations

17. About Us & Disclaimer